Cleerly has raised $106 million in a Series C extension funding round.
The company said it will use the investments for commercial growth and clinical evidence generation around its AI-enabled CT technologies that have been cleared by the U.S. Food and Drug Administration (FDA).
Cleerly’s software is designed to identify heart disease by analyzing noninvasive images. In the announcement, James Min, MD, founder and CEO, noted recent achievements in attaining Medicare coverage and a Current Procedural Terminology (CPT) Category I code for coronary plaque analysis.
The funding round was led by global software investor Insight Partners and joined by Battery Ventures, with participation from preexisting investors, Cleerly said.
